Sold as Ticar. Every FDA application for this active ingredient: 1 branded and 1 generic.
As of Nov 15, 2026, FDA lists 2 applications for Ticarcillin Disodium (sold as Ticar), first approved Nov 9, 1976, with 0 new uses approved and 0 published complete response letters.
| Nov 9, 1976 | TicarNDA 50497 ยท New molecular entity | Glaxosmithkline | 23 | Discontinued |
| Dec 19, 1986 | TicarANDA 62690 | Glaxosmithkline | 4 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Glaxosmithkline